Jane Street’s Amylyx Pharmaceuticals AMLX Stock Holding History

Jane Street’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$190K	Sell	13,700 -17,400	-56%	-$245K	﹤0.01%	10197
2025 Q4	$376K	Sell	31,100 -21,400	-41%	-$291K	﹤0.01%	8339
2025 Q3	$713K	Buy	+52,500	New	+$494K	﹤0.01%	7055
2024 Q2	–	Sell	-260,500	Closed	-$740K	–	9276
2024 Q1	$740K	Buy	260,500 +39,000	+18%	+$510K	﹤0.01%	5985
2023 Q4	$3.26M	Sell	221,500 -56,900	-20%	-$872K	﹤0.01%	3508
2023 Q3	$5.1M	Buy	278,400 +33,800	+14%	+$715K	﹤0.01%	2586
2023 Q2	$5.28M	Sell	244,600 -30,100	-11%	-$813K	﹤0.01%	2657
2023 Q1	$8.06M	Buy	274,700 +145,900	+113%	+$5.07M	﹤0.01%	1861
2022 Q4	$4.76M	Sell	128,800 -40,200	-24%	-$1.43M	﹤0.01%	2557
2022 Q3	$4.76M	Buy	169,000 +146,200	+641%	+$3.65M	﹤0.01%	2711
2022 Q2	$439K	Buy	+22,800	New	+$271K	﹤0.01%	6966

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Jane Street's AMLX Position: Q1 2026 in Review

Jane Street sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 263,235 shares — an estimated $3.7M sold.

Jane Street first reported a position in AMLX in Q1 2022 and held it in 14 quarters. The position peaked at $17M in Q4 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Jane Street reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Jane Street sold 263,235 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $3.7M.
Jane Street first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 14 quarters.
Jane Street's Amylyx Pharmaceuticals position peaked at $17M in Q4 2023.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.